GET DAILY SIGNALSCellebrite (CLBT): Can Shares Reach the $15 Analyst Target for +38% Upside?
Key Takeaways
- The central target of $15 is the arithmetic mean of six verified, current analyst price targets, rounded to a clean level; the underlying mean is roughly $14.67.
- With shares trading near $10.90 following the third-quarter 2026 report, reaching $15 implies roughly 38% upside, a substantial move.
- Individual targets cluster tightly, from about $13 to $16; all six analysts rate the stock Buy or Overweight, with no hold or sell ratings.
- The strongest support is improving profitability and cash generation—20% annual recurring revenue (ARR) growth, a 36% adjusted EBITDA margin, and accelerating U.S. federal demand.
- The biggest risks are repeated revenue guidance trims, the unresolved CFIUS review of the Corellium acquisition, and a still-expensive valuation.
- For more context on the ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages for deeper analysis.
- Readers can also explore Trending AI Robots for AI-driven trade ideas across the market.
What Analysts Are Targeting for CLBT
Six current, individually verifiable targets were reviewed. The most recent include DA Davidson ($15, Buy), Lake Street ($15, Buy), and TD Cowen ($15, Buy), alongside J.P. Morgan ($16, Overweight), Deutsche Bank ($14, Buy), and Needham ($13, Buy), most set or reiterated between August and September 2026. The arithmetic mean of these six is approximately $14.67, which rounds to a $15 central target; the range is relatively tight at roughly $13 to $16. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Notably, these figures reflect a significant reset. After the company's August 2026 guidance cut and CEO transition, several firms lowered targets—TD Cowen cut from $23 to $15, while J.P. Morgan and Deutsche Bank trimmed from $20 to $16 and $14, respectively. DA Davidson initiated coverage with a Buy in May 2026. Because third-party aggregators sometimes still carry older, higher targets from before that reset, published "consensus" figures vary; the $15 figure here is the calculated mean of the current targets identified, not an official published consensus.
Current Price Level and the Road to $15
Shares closed near $10.90 in mid-November 2026, down roughly 14% in a single session after the third-quarter report, leaving the stock down about 29% year to date and near the lower end of its 52-week range of $9.58 to $19.98. Reaching $15 requires about 38% upside—a substantial move that would still leave the stock well below its 52-week high.
The path depends on restoring confidence in the revenue outlook. Third-quarter results were strong on profitability: revenue rose 18% to $149 million, ARR grew 20% to $528.5 million, and adjusted EBITDA jumped 42% to $53.6 million (a 36% margin). But management trimmed full-year revenue guidance to $553–$558 million and reiterated, rather than raised, its ARR outlook, signaling continued top-line caution. A sustained re-acceleration of ARR and successful conversion of the remaining installed base to the Inseyets platform would be the clearest route back toward $15.
Factors That Could Support a Recovery
- Profitability and cash flow: A 36% adjusted EBITDA margin and trailing-12-month free cash flow margin near 31% demonstrate improving operating leverage.
- Recurring revenue: Subscription revenue reached 91% of total revenue, with net revenue retention (NRR) of 116%, indicating existing customers are expanding.
- U.S. federal re-acceleration: Federal growth improved from flat in 2025 to 18% in the third quarter, including the company's first large FedRAMP deal and its largest Guardian win to date.
- New AI products: The Genesis agentic-AI offering reached $2 million in ARR in its first full quarter, which management called the strongest product launch in company history.
- Balance sheet: Roughly $593 million in cash and minimal debt provide flexibility for execution and potential share support.
Risks That Could Hold the Stock Back
- Guidance erosion: Full-year revenue guidance has been trimmed multiple times in 2026, and fourth-quarter guidance implies a flat-to-lower sequential quarter.
- Corellium uncertainty: The acquisition remains under CFIUS review, and Corellium's ARR has disappointed, with elevated churn and delayed renewals.
- Valuation: Even after the decline, shares trade at a trailing P/E ratio above 50, leaving limited room for further execution missteps.
- Lighter conversion uplift: Management cautions that the final tranche of Inseyets conversions will produce less uplift than prior years.
- Momentum and sentiment: The stock sits below both its 50-day and 200-day moving averages, reflecting persistent investor skepticism.
Technical Levels Worth Watching
After the November 2026 decline, Cellebrite trades below its 50-day moving average near $11.60 and its 200-day moving average near $13.20. The 200-day average now represents an important resistance zone on any recovery, followed by the $15 target area itself. On the downside, the $10 psychological level and the 52-week low near $9.58 are the key support zones to watch. The 52-week high near $20 marks the ceiling of the stock's broader range and remains far above current levels.
Key Items to Monitor Going Forward
Analyst price targets typically reflect a roughly 12-month horizon, though the firms reviewed do not always publish identical time frames, and the August 2026 target cuts show how quickly these estimates can shift. Investors should watch the next quarterly report for signs that ARR growth holds near 20%, whether full-year revenue and ARR guidance is raised or held, the resolution of the Corellium CFIUS review, continued U.S. federal and international demand, and any analyst target revisions following results. Margin trends and free-cash-flow conversion will matter as much as the headline top line. From what I see, the technical setup also deserves close attention here.
Exploring AI Daily Buy/Sell Signals
For traders who want to track shifting momentum rather than rely on static price targets, Tickeron's AI Daily Buy/Sell Signals offer a complementary, data-driven tool. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. In my view, it helps spot emerging trend changes more efficiently than manual screening allows, and I find it useful to cross-check ideas alongside the fundamentals discussed here.
Final Assessment
Whether CLBT can reach $15 depends less on a single quarter than on restoring confidence in its growth trajectory. The $15 central target, the mean of six current analyst targets, sits about 38% above the recent price—a substantial climb that reflects a favorable long-term view tempered by a clear near-term reset. Strong profitability, expanding recurring revenue, a strengthening federal franchise, and early AI momentum provide genuine support. Against that stand repeated guidance trims, the unresolved Corellium review, a rich valuation, and weak technical momentum. The next earnings report and any resolution of the CFIUS process will be the key signposts for whether the market begins pricing in that upside.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CLBT in upward trend: price rose above 50-day moving average on October 21, 2026
CLBT moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 29 of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on CLBT as a result. In 71 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The 10-day moving average for CLBT crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +2.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLBT advanced for three days, in 221 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 169 of 214 cases where CLBT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for CLBT moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 31 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
CLBT broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. CLBT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 63 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.815) is normal, around the industry mean (16.272). P/E Ratio (51.875) is within average values for comparable stocks, (52.956). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.430) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (103.889).
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ComputerCommunications
Advertisement